In the highly competitive pharmaceutical services sector, avid bidding for prominent businesses have observed an exponential acceleration as new players and investors are showing everyday interest. This surge in investors, who previously didn’t focus much on the pharma sector, has necessitated an urgent understanding of central considerations for due diligence. These considerations significantly influence risk allocation and in several instances, the valuation of the firms as well.
A notable trend in the sector is the rise in acquisitions of Contract Research Organizations (CROs). As these transactions typically carry a unique set of diligence challenges and opportunities, it’s crucial for potential acquirers to identify and understand key issues.
The due diligence process for a CRO acquisition involves various stages, including understanding the company’s contractual relationships, assessing the organization structure and liabilities, examining intellectual property rights, conducting tax due diligence, ensuring regulatory compliance, and employment or labor matters.
All this gives rise to questions which are critical in assessing the viability of the CRO for acquisition, such as the detailed examination of the quality of the CRO’s services, its compliance with healthcare laws and regulations, its workforce’s capabilities, development, and retention strategies among others.
The inherent urgency and the complexity of the acquisitions are driving investors towards a sprint to navigate these due diligence considerations. This, in turn, dictates risk allocation and affects the ultimate deal value in the pharmaceutical space.
More details on these diligence considerations can be found here courtesy of McGuireWoods LLP, shedding valuable light on these sequential processes, critical elements, and their impact on the fast-paced pharmaceutical industry.